and protriptyline both increase sedation. Use Caution/Monitor.pyridostigminepyridostigmine increases and amoxapine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.quazepamquazepam and amoxapine both increase sedation. Use Caution/Monitor.quetiapinequetiapine and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.quetiapine and amoxapine both increase sedation. Use Caution/Monitor.quetiapine, amoxapine. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT.quinineamoxapine and quinine both increase QTc interval. Use Caution/Monitor.ramelteonamoxapine and ramelteon both increase sedation. Use Caution/Monitor.ranolazineamoxapine and ranolazine both increase QTc interval. Modify Therapy/Monitor Closely.rapacuroniumrapacuronium and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.remimazolamremimazolam, amoxapine. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely. Coadministration may result in profound sedation, respiratory depression, coma, and/or death. Continuously monitor vital signs during sedation and recovery period if coadministered. Carefully titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics.rifabutinrifabutin decreases levels of amoxapine by increasing metabolism. Use Caution/Monitor.rilpivirinerilpivirine increases toxicity of amoxapine by QTc interval. Use Caution/Monitor. Rilpivirine should be used with caution when co-administered with a drug with a known risk of Torsades de Pointes.risperidoneamoxapine and risperidone both increase QTc interval. Modify Therapy/Monitor Closely.risperidone and amoxapine both increase sedation. Use Caution/Monitor.rizatriptanrizatriptan and amoxapine both increase serotonin levels. Modify Therapy/Monitor Closely.rocuroniumrocuronium and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.rolapitantrolapitant will increase the level or effect of amoxapine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Rolapitant may increase plasma concentrations of CYP2D6 substrates for at least 28 days following rolapitant administration.romidepsinamoxapine and romidepsin both increase QTc interval. Modify Therapy/Monitor Closely.salmeterolamoxapine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.SAMeamoxapine and SAMe both increase serotonin levels. Modify Therapy/Monitor Closely.scopolaminescopolamine and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.scullcapamoxapine and scullcap both increase sedation. Use Caution/Monitor.secobarbitalsecobarbital and amoxapine both increase sedation. Use Caution/Monitor.selpercatinibselpercatinib increases toxicity of amoxapine by QTc interval. Use Caution/Monitor.sertralinesertraline and amoxapine both increase QTc interval. Use Caution/Monitor.shepherd's purseamoxapine and shepherd's purse both increase sedation. Use Caution/Monitor.sodium sulfate/?magnesium sulfate/potassium chloridesodium sulfate/?magnesium sulfate/potassium chloride increases effects of amoxapine by unknown mechanism. Use Caution/Monitor. Closely monitor for evidence of seizures when using higher dose of magnesium sulfate together with drugs that lower the seizure threshold.sodium sulfate/potassium chloride/magnesium sulfate/polyethylene glycolamoxapine, sodium sulfate/potassium chloride/magnesium sulfate/polyethylene glycol. Other (see comment). Use Caution/Monitor. Comment: Caution when bowel preps are used with drugs that cause SIADH or NSAIDs; increased risk for water retention or electrolyte imbalance.sodium sulfate/potassium sulfate/magnesium sulfatesodium sulfate/potassium sulfate/magnesium sulfate increases effects of amoxapine by unknown mechanism. Use Caution/Monitor. Closely monitor for evidence of seizures when using higher dose of magnesium sulfate together with drugs that lower the seizure threshold.solifenacinsolifenacin and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.solifenacin and amoxapine both increase QTc interval. Use Caution/Monitor.sorafenibsorafenib and amoxapine both increase QTc interval. Use Caution/Monitor.stiripentolstiripentol, amoxapine. Either increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence.succinylcholinesuccinylcholine increases and amoxapine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.sufentanilsufentanil and amoxapine both increase sedation. Use Caution/Monitor.sufentanil SLsufentanil SL, amoxapine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.sulfamethoxazoleamoxapine and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.sumatriptansumatriptan and amoxapine both increase serotonin levels. Modify Therapy/Monitor Closely.sumatriptan intranasalsumatriptan intranasal and amoxapine both increase serotonin levels. Modify Therapy/Monitor Closely.suvorexantsuvorexant and amoxapine both increase sedation. Modify Therapy/Monitor Closely. Dosage adjustments of suvorexant and concomitant CNS depressants may be necessarytapentadoltapentadol and amoxapine both increase sedation. Use Caution/Monitor.amoxapine and tapentadol both increase serotonin levels. Modify Therapy/Monitor Closely.telavancinamoxapine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.temazepamtemazepam and amoxapine both increase sedation. Use Caution/Monitor.terbinafineterbinafine will increase the level or effect of amoxapine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Assess need to reduce dose of CYP2D6-metabolized drug.terbutalineamoxapine increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.tetrabenazineamoxapine and tetrabenazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.thioridazinethioridazine and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.thioridazine and amoxapine both increase sedation. Use Caution/Monitor.thiothixenethiothixene and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.thiothixene and amoxapine both increase sedation. Use Caution/Monitor.thyroid desiccatedthyroid desiccated increases effects of amoxapine by Other (see comment). Use Caution/Monitor. Comment: Increased catecholamine receptor sensitivity; may increase CNS and cardiovascular effects, including arrhythmias.tiotropiumtiotropium and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.tolterodinetolterodine and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.topiramateamoxapine and topiramate both increase sedation. Modify Therapy/Monitor Closely.tramadoltramadol and amoxapine both increase sedation. Use Caution/Monitor.amoxapine and tramadol both increase serotonin levels. Modify Therapy/Monitor Closely.trazodoneamoxapine and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.amoxapine and trazodone both increase sedation. Use Caution/Monitor.triazolamtriazolam and amoxapine both increase sedation. Use Caution/Monitor.triclofostriclofos and amoxapine both increase sedation. Use Caution/Monitor.trifluoperazinetrifluoperazine and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.trifluoperazine and amoxapine both increase sedation. Use Caution/Monitor.trihexyphenidyltrihexyphenidyl and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor. Potential for additive anticholinergic effects.trimethoprimamoxapine and trimethoprim both increase QTc interval. Modify Therapy/Monitor Closely.trimipramineamoxapine and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.amoxapine and trimipramine both increase sedation. Use Caution/Monitor.triprolidinetriprolidine and amoxapine both increase sedation. Use Caution/Monitor.tropisetronamoxapine and tropisetron both increase QTc interval. Modify Therapy/Monitor Closely.trospium chloridetrospium chloride and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.valbenazinevalbenazine and amoxapine both increase QTc interval. Use Caution/Monitor.valerianvalerian and amoxapine both increase sedation. Use Caution/Monitor.vecuroniumvecuronium and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.venlafaxineamoxapine and venlafaxine both increase QTc interval. Modify Therapy/Monitor Closely.voclosporinvoclosporin, amoxapine. Either increases effects of the other by QTc interval. Use Caution/Monitor.voriconazoleamoxapine and voriconazole both increase QTc interval. Modify Therapy/Monitor Closely.xylometazolineamoxapine increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.yohimbineamoxapine increases and yohimbine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.ziconotideamoxapine and ziconotide both increase sedation. Use Caution/Monitor.ziprasidoneziprasidone and amoxapine both increase sedation. Use Caution/Monitor.zolmitriptanzolmitriptan and amoxapine both increase serotonin levels. Modify Therapy/Monitor Closely.Minor (71)acarboseamoxapine increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.amobarbitalamobarbital, amoxapine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.atropineamoxapine increases levels of atropine by unknown mechanism. Minor/Significance Unknown.atropine IV/IMamoxapine increases levels of atropine IV/IM by unknown mechanism. Minor/Significance Unknown.bazedoxifene/conjugated estrogensbazedoxifene/conjugated estrogens, amoxapine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.brimonidineamoxapine decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.butabarbitalbutabarbital, amoxapine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.butalbitalbutalbital, amoxapine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.carbamazepinecarbamazepine decreases levels of amoxapine by increasing metabolism. Minor/Significance Unknown.chlorpromazineamoxapine, chlorpromazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.amoxapine, chlorpromazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.chlorpropamideamoxapine increases effects of chlorpropamide by pharmacodynamic synergism. Minor/Significance Unknown.conjugated estrogensconjugated estrogens, amoxapine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.conjugated estrogens, vaginalconjugated estrogens, vaginal, amoxapine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.desfluranedesflurane, amoxapine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.dexmethylphenidatedexmethylphenidate increases effects of amoxapine by decreasing metabolism. Minor/Significance Unknown.estradiolestradiol, amoxapine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.estrogens conjugated syntheticestrogens conjugated synthetic, amoxapine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.estrogens esterifiedestrogens esterified, amoxapine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens may inhibit hepatic metabolism of tricyclic antidepressants. However, interactions are not common.estropipateestropipate, amoxapine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.ethinylestradiolethinylestradiol, amoxapine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.etomidateetomidate, amoxapine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.eucalyptusamoxapine and eucalyptus both increase sedation. Minor/Significance Unknown.fluphenazineamoxapine, fluphenazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.amoxapine, fluphenazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.fluphenazine, amoxapine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.glimepirideamoxapine increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown.glipizideamoxapine increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown.glyburideamoxapine increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown.hydroxyprogesterone caproate (DSC)hydroxyprogesterone caproate (DSC), amoxapine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.insulin aspartamoxapine increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.insulin detemiramoxapine increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown.insulin glargineamoxapine increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown.insulin glulisineamoxapine increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown.insulin lisproamoxapine increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown.insulin NPHamoxapine increases effects of insulin NPH by pharmacodynamic synergism. Minor/Significance Unknown.insulin regular humanamoxapine increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown.isoproterenolisoproterenol, amoxapine. Mechanism: unknown. Minor/Significance Unknown. Risk of cardiac arrhythmias.ketamineketamine, amoxapine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.lithiumlithium, amoxapine. Other (see comment). Minor/Significance Unknown. Comment: Risk of neurotoxicity in geriatric pts. Multiple mechanisms involved.mestranolmestranol, amoxapine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.metforminamoxapine increases effects of metformin by pharmacodynamic synergism. Minor/Significance Unknown.miglitolamoxapine increases effects of miglitol by pharmacodynamic synergism. Minor/Significance Unknown.nateglinideamoxapine increases effects of nateglinide by pharmacodynamic synergism. Minor/Significance Unknown.panax ginsengpanax ginseng increases effects of amoxapine by pharmacodynamic synergism. Minor/Significance Unknown.pentobarbitalpentobarbital, amoxapine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.perphenazineamoxapine, perphenazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.amoxapine, perphenazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.phenobarbitalphenobarbital, amoxapine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.pioglitazoneamoxapine increases effects of pioglitazone by pharmacodynamic synergism. Minor/Significance Unknown.pleurisy rootpleurisy root decreases effects of amoxapine by unspecified interaction mechanism. Minor/Significance Unknown. Theoretical interaction.primidoneprimidone, amoxapine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.prochlorperazineamoxapine, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.amoxapine, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.progesterone micronizedprogesterone micronized, amoxapine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.promazineamoxapine, promazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.amoxapine, promazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.promethazineamoxapine, promethazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.amoxapine, promethazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.promethazine, amoxapine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.propofolpropofol,